1 completed, 1 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow CNS Metastases: new trials by email Literature Review of CNS Metastases trials Research Report on CNS Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases 131I-omburtamab - Neuroblastoma, CNS Metastases | Phase 2 / Phase 3 | Terminated | Y-mAbs Therapeutics | 52 | 2018-12-11 | 2024-02-13 |
Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Meningeal Carcinomatosis (1) · Meningioma (1) · Multiple Sclerosis (1) · Neoplasms (1) · Neurilemmoma (1) · Neuroblastoma (1) · Neurofibroma (1) · Neuroinflammatory Diseases (1) · Neuroma, Acoustic (1)
Meningeal Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neuroectodermal Tumors (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1)
Carboplatin (1) · Dexamethasone (1) · Etoposide (1) · Ifosfamide (1) · Mn-PyC3A (1) · omburtamab I-131 (1) · selinexor (1)
Reveal Pharmaceuticals Inc. (1) · Samsung Medical Center (1) · Y-mAbs Therapeutics (1)
United States (2) · Denmark (1) · Japan (1) · South Korea (1) · Spain (1)
John Roemer, MD (1) · Seok Jin Kim (1)
R44CA261240 (1)